Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct;29(44):2400680.
doi: 10.2807/1560-7917.ES.2024.29.44.2400680.

Effectiveness of the autumn 2023 COVID-19 vaccine dose in hospital-based healthcare workers: results of the VEBIS healthcare worker vaccine effectiveness cohort study, seven European countries, season 2023/24

Camelia Savulescu  1   2 , Albert Prats-Uribe  1   2 , Kim Brolin  3 , Anneli Uusküla  4 , Colm Bergin  5 , Catherine Fleming  6 , Rita Murri  7   8 , Viesturs Zvirbulis  9 , Dace Zavadska  10 , Vania Gaio  11 , Corneliu P Popescu  12   13 , Raluca Hrisca  14 , Maria Cisneros  15   16 , Miriam Latorre-Millán  17 , Liis Lohur  18 , Jonathan McGrath  5 , Lauren Ferguson  6 , Katleen De Gaetano Donati  7   8 , Ilze Abolina  9 , Dagne Gravele  10 , Ausenda Machado  11 , Simin-Aysel Florescu  12   13 , Mihaela Lazar  19 , Pilar Subirats  20 , Laura Clusa Cuesta  17 , Jacklyn Sui  5 , Claire Kenny  6 , Rosaria Santangelo  7   8 , Dainis Krievins  9 , Elza Anna Barzdina  10 , Camila Valadas Henriques  21 , Alma Gabriela Kosa  12 , Saftica-Mariana Pohrib  14 , Carmen Muñoz-Almagro  15   16   22 , Ana Milagro  17 , Sabrina Bacci  3 , Anthony Nardone  1 ; VEBIS HCW VE study group  23 ; Collaborators in VEBIS HCW study group
Collaborators, Affiliations

Effectiveness of the autumn 2023 COVID-19 vaccine dose in hospital-based healthcare workers: results of the VEBIS healthcare worker vaccine effectiveness cohort study, seven European countries, season 2023/24

Camelia Savulescu et al. Euro Surveill. 2024 Oct.

Abstract

COVID-19 vaccination recommendations include healthcare workers (HCWs). We measured COVID-19 vaccine effectiveness (CVE) of the autumn 2023 dose against laboratory-confirmed SARS-CoV-2 infection in a prospective cohort study of 1,305 HCWs from 13 European hospitals. Overall CVE was 22% (95% CI: -17 to 48), 49% (95% CI: -8 to 76) before and -11% (95% CI: -84 to 34) after the start of BA.2.86/JN.1 predominant circulation. Autumn 2023 COVID-19 vaccination led to a moderate-to-low reduction in SARS-CoV-2 infection incidence in HCWs. Monitoring of CVE is crucial for COVID-19 prevention.

Keywords: COVID-19; Europe; Healthcare workers; SARS-CoV-2; Vaccine effectiveness.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: APU reported payment under EMA DARWIN EU project outside of the submitted work. MLM, AM, LC reported additional support received from ISIDORe (EATRIS) Network for carrying out the local SARS-CoV-2 sequencing. CPP, SAF reported speaker fees from and participation in Advisory board of Pfizer and MSD. SAF reports also participation in Advisory board of Gilead. CMA reported speaker fees from MSD, Pfizer and Sanofi. JS reported support for attending ESID conference 2022 from Takeda Pharmaceutical. RH and SP reported grant attributed to their institution on “PSCD Longitudinal evaluation of SARS CoV-2 immune status post-natural infection and post-vaccination”. All other authors declare no conflicts of interest related to this work.

Figures

Figure 1
Figure 1
Inclusion and exclusion criteria, VEBIS healthcare worker multicentre cohort study on COVID-19 vaccine effectiveness, seven European countries, season 2023/24 (n = 1,483)
Figure 2
Figure 2
Kaplan-Meier plots of time (days) from enrolment to SARS-CoV-2 infection in VEBIS healthcare worker multicentre cohort study on COVID-19 vaccine effectiveness, by vaccination status, seven European countries, season 2023/24 (n = 1,305)
See this image and copyright information in PMC

References

    1. European Centre for Disease Prevention and Control (ECDC). ECDC-EMA statement on updating COVID-19 vaccines composition for new SARS-CoV-2 virus variants. Amsterdam: EMA; Stockholm: ECDC; 2023. Available from: https://www.ecdc.europa.eu/en/news-events/ecdc-ema-statement-updating-co...
    1. World Health Organization (WHO). WHO roadmap on uses of COVID-19 vaccines in the context of Omicron and high population immunity. Geneva: WHO; 2023. Available from: https://iris.who.int/bitstream/handle/10665/373987/WHO-2019-nCoV-Vaccine...
    1. European Centre for Disease Prevention and Control (ECDC). The European Respiratory Virus Surveillance Summary (ERVISS). Stockholm: ECDC. [Accessed: 11 Jun 2024]. Available from: https://www.ecdc.europa.eu/en/publications-data/european-respiratory-vir...
    1. European Centre for Disease Prevention and Control (ECDC). Generic protocol for ECDC studies of COVID-19 vaccine effectiveness against confirmed SARS-CoV-2 using healthcare worker cohorts, version 3.0 . Stockholm: ECDC; 2024. Available from: https://www.ecdc.europa.eu/en/publications-data/generic-protocol-ecdc-st...
    1. European Centre for Disease Prevention and Control (ECDC). Reinfection with SARS-CoV-2: implementation of a surveillance case definition within the EU/EEA. Stockholm: ECDC; 2021. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/Reinfection-wit...

Substances

LinkOut - more resources